MedTrace Logo

BIO-PREDISC-TIA SWISS Cohort Study

NCT03994003 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-04-18

No results posted yet for this study

Summary

This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.

Conditions

  • Cerebrovascular Disease, Ischemic Stroke

Sponsors & Collaborators

  • Ente Ospedaliero Cantonale, Bellinzona

    collaborator OTHER

  • Dr. med. Carlo Cereda

    lead OTHER_GOV

Principal Investigators

  • Carlo Cereda, MD · Neurocentro della Svizzera Italiana Ospedale Regionale di Lugano

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-04
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03994003 on ClinicalTrials.gov